SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 367.36 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 144.68 |
| Book Value / Share | 1.54 |
| Price / Book | n/a |
| NCAV ($M) | 87.27 |
| NCAV / Share | 0.93 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.37 |
| Return on Assets (ROA) | -0.35 |
| Return on Equity (ROE) | -0.39 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.78 |
| Current Ratio | 7.78 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 109.87 |
| Assets | 167.28 |
| Liabilities | 22.60 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 14.80 |
| Operating Income | -53.62 |
| Net Income | -54.23 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -60.41 |
| Cash from Investing | 65.64 |
| Cash from Financing | 43.25 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | AFFiRiS AG | 6.66 | -2.18 | |
| 13G/A | Biotechnology Value Fund L P | 14.80 | 96.16 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 47,945 | 188,611 | 25.42 | |
| 188,419 | 636,854 | 29.59 | |
| 15,689 | 98,251 | 15.97 | |
| 15,357 | 89,352 | 17.19 | |
| 15,966 | 113,312 | 14.09 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACAB – Atlantic Coastal Acquisition Corp. II | ACET – Adicet Bio, Inc. |
| ACRV – Acrivon Therapeutics, Inc. | ADMA – ADMA Biologics, Inc. |
Financial data and stock pages provided by
Fintel.io